The government is now operating in accordance with the Guidance on Caretaker Conventions, pending the outcome of the 2025 federal election.
Use the filters below to narrow your search.
Filter results
You can narrow down the results using the filters.
- (-) Medicine safety (159)
- (-) In Vitro Diagnostic medical devices (IVDs) (11)
- (-) Weight loss products (8)
- Advertising (248)
- COVID-19 (144)
- Prescription medicines (139)
- Regulatory compliance (128)
- COVID-19 vaccines (88)
- Legislation (81)
- Therapeutic goods regulation (75)
- Listed medicines (54)
- Non-prescription medicines (50)
- Safety (48)
- Medical devices safety (43)
- Vaping hub (39)
- Complementary medicines (33)
- Manufacturing (33)
- Labelling and packaging (28)
- Assessed listed medicines (26)
- Over the counter (OTC) medicines (25)
- Scheduling (national classification system) (24)
- Australian Register of Therapeutic Goods (ARTG) (22)
- Compliance and enforcement hub (22)
- Medicinal cannabis hub (21)
- Import and export (19)
- Alert/Advisory (18)
- Shortages (12)
- Sunscreens (8)
- Advisory bodies and committees (5)
- Clinical trials (3)
- Cosmetics (3)
- Blood and blood components (2)
- Fees and payments (2)
- Prescription opioids hub (2)
- Registered complementary medicines (2)
- Unique Device Identification (UDI) hub (2)
- Advanced therapies (1)
- Biological medicines (1)
- Blood safety (1)
- Breast implant hub (1)
- Travelling with health products (1)
Filters applied:Clear all
Search
176 result(s) found, displaying 1 to 25
-
Compliance undertakingsWe have accepted a court-enforceable undertaking from Your Solution Compounding Pharmacy Pty Ltd, regarding advertising of prescription-only compounded medicines for weight-loss.
-
Media releasesWe have accepted a court-enforceable undertaking from Your Solution Compounding Pharmacy Pty Ltd, regarding advertising of prescription-only compounded medicines for weight-loss.
-
Safety updatesUpdates further highlight potential risks of mood-related changes and sexual disorders.
-
Safety updatesInformation for health professionals about medicines with safety related updates to their Product Information.
-
Safety updatesMore prominent warnings are being added to the product information (PI) and consumer medicine information (CMI) for all oral and injectable (systemic) fluoroquinolones to strengthen existing warnings about serious side effects
-
Safety updatesThere may be an increased risk of neurodevelopmental disorders in children born to men who have taken sodium valproate in the 3 months before conception.
-
NewsFollowing a request from the sponsor to reconsider their decision, the TGA has confirmed the initial decision to not register the medicine on the basis that the safety and efficacy of the medicine were not satisfactorily established.
-
NewsWe are updating information for nitrosamine impurities and other nitroso-structure impurities in medicines including acceptable intakes (AI)
-
Safety updatesInformation for health professionals about medicines with safety related updates to their Product Information.
-
BlogAustralians who use tanning products containing ‘melanotan’ are at risk of serious health problems.
-
Safety updatesInformation for health professionals about medicines with safety related updates to their Product Information.
-
Safety updatesAdditional safety information is being added to all montelukast products to strengthen and highlight existing warnings about serious neuropsychiatric events.
-
NewsRecall reforms program update and preview of the PRAC Version 1.0.
-
Safety updatesTCMs sold in Australia are carefully regulated to ensure safety and quality.
-
Safety updatesInformation for health professionals about medicines with safety related updates to their Product Information.
-
Safety updatesInformation for health professionals about medicines with safety related updates to their Product Information.
-
Safety updatesHealth professionals and consumers are advised that the oral antihistamine promethazine hydrochloride, sold as Phenergan and other generic brands, should not be used in children under 6 years of age.
-
Safety updatesWe have received Australian reports of Guillain-Barré Syndrome (GBS) following Shingrix vaccination.
-
Safety updatesInformation for health professionals about medicines with safety related updates to their Product Information.
-
NewsThe TGA is updating information for nitrosamine impurities in medicines including acceptable intakes (AI).
-
NewsTGA has made the decision not to register lecanemab (LEQEMBI) for the treatment of patients with Mild Cognitive Impairment (MCI) due to Alzheimer's disease and Mild Alzheimer's dementia (early Alzheimer's disease).
-
NewsFollowing our Essential Principles presentations on 11-12 September 2024, we have collated questions asked into themes to simplify finding information of relevance to you.
-
NewsThe Prescription Medicines in Pregnancy database has been updated to include new and amended entries.
-
Safety updatesInformation for health professionals about medicines with safety related updates to their Product Information.
-
Safety updatesInformation for health professionals about medicines with safety related updates to their Product Information.